Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2026)

Rigel Pharmaceuticals' Non-Current Debt history runs 8 years deep, the most recent figure standing at $15.0 million for Q1 2026.

• On a quarterly basis, Non-Current Debt fell 66.64% year-over-year to $15.0 million in Q1 2026; TTM through Mar 2026 was $15.0 million, a 66.64% decrease from a year earlier, with the FY2025 full-year figure at $52.3 million, down 12.38% from the prior year.
• Non-Current Debt retreated to $15.0 million in Q1 2026 per RIGL's latest filing, from $52.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $59.8 million in Q3 2024 and bottomed at $15.0 million in Q1 2026.
• The 5-year median for Non-Current Debt is $44.9 million (2025), against an average of $45.5 million.
• Across the five-year window, Non-Current Debt soared 99.68% in 2023 and tumbled 66.64% in 2026, its largest moves.
• Year by year, Non-Current Debt stood at $39.4 million in 2022, then jumped by 32.76% to $52.4 million in 2023, then advanced by 13.95% to $59.7 million in 2024, then declined by 12.38% to $52.3 million in 2025, then sank by 71.33% to $15.0 million in 2026.
• Per Business Quant, the three latest RIGL Non-Current Debt figures stand at $15.0 million (Q1 2026), $52.3 million (Q4 2025), and $30.0 million (Q3 2025).